Slingshot members are tracking this corporate initiative:
Eli Lilly to Acquire AurKa Pharma
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|LLY||Community voting in process|
Aurora kinases are believed to play a crucial role in cellular division by controlling chromosomal segregation. Defects in segregation can cause genetic instability, a condition highly associated with the formation of tumors. Aurora kinases, consisting of Aurora A, Aurora B and Aurora C, are key mitotic regulators required for genome stability and are frequently overexpressed in cancerous tumors. AurKa Pharma's asset, AK-01, has been shown to be highly selective for Aurora A, with potential clinical benefit observed in Phase 1 studies. Future studies will seek to determine if the selectivity profile of AK-01 can improve efficacy while limiting toxicity risks to a manageable level.After a review of its clinical pipeline priorities in 2016, Lilly sold the compound to TVM Capital Life Science, which then established AurKa as part of the TVM Life Science Ventures VII fund. The fund is a novel investment model that seeks to develop early-stage pharmaceutical assets in a capital-efficient manner. As part of its innovation strategy, Lilly actively participates with venture capital firms to source early stage opportunities.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: May 14, 2018 Projected Implementation: Q2, 2018 Relevance Tracked Until: Q3, 2018
Don’t see a project related to the strategic initiative you care about?
Related Keywords Solid Tumors, Ak-01